is tirzepatide a glp 1 or 2 Designing dual GLP-1R/GIPR agonist from | DDDT GLP-1 and Inflammation: How These

Bartke A

Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD

It further elaborates on the core mechanisms underlying platinum accumulation-mediated multi-organ toxicity, including nephrotoxicity, neurotoxicity, and ototoxicity